Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Genflow Biosciences Plc ( (GB:GENF) ) is now available.
Genflow Biosciences Plc has successfully administered its proprietary SIRT6-centenarian gene therapy for the second time in a clinical trial involving elderly dogs, demonstrating excellent safety and tolerability. This milestone highlights the potential of Genflow’s gene therapy platform to extend beyond human health into the lucrative global animal health market, with plans to advance its animal health initiative further. The company is committed to leveraging its innovative gene therapy platform to create value for shareholders and establish partnerships in the field of genetic longevity therapeutics.
More about Genflow Biosciences Plc
Genflow Biosciences Plc, founded in 2020 and headquartered in the UK with R&D facilities in Belgium, is a biotechnology company focused on developing gene therapies to slow down the aging process. The company’s lead compound, GF-1002, involves the delivery of a centenarian variant of the SIRT6 gene, which has shown promising results. Genflow aims to promote longer and healthier lives and is also exploring treatments for chronic liver disease.
Average Trading Volume: 6,858,333
Technical Sentiment Signal: Buy
Find detailed analytics on GENF stock on TipRanks’ Stock Analysis page.